Stephen A Williams MD PhD
Chief Medical Officer, Somalogic Inc
Susan M. Domchek, MD
Basser Professor in Oncology at the Perelman School of Medicine of the University of Pennsylvania. Executive Director of the Basser Center for BRCA at the Abramson Cancer Center and Director of the Mariann and Robert MacDonald Cancer Risk Evaluation Center
Giorgio Sirugo, MD, PhD
Co-Director Center Penn Medicine Biobank and adjunct Associate Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine.
Michael Montalto, PhD
Vice President and Head of Translational Sciences at Bristol-Myers Squibb
Michael Rivers
Vice President and Lifecycle Leader, Digital Pathology – Roche Tissue Diagnostics
Grace Cordovano, PhD
CEO & Founder , Enlightening Results, LLC
Jeffrey Shaman, PhD.MS
Chief Scientific Officer, Coriell Life Sciences
Reto Merges
Global Head of Expanding Precision Medicine Siemens Healthineers
Kimberley Ferguson
Market Development Executive, Roche Diagnostics Information Systems
Gary Palmer, MD, JD, MBA, MPH
Chief Medical Officer, Tempus Labs, Inc.
Dwight Raum
Vice President and Chief Technology Officer of Johns Hopkins Health System and Johns Hopkins University
Ben Zeskind, PhD, MBA
Co-Founder and CEO, Immuneering
Damian P. Alagia III, MD, MS, MBA, FACS, FACOG
Franchise Medical Director for Women’s Health and Reproductive Medicine for Quest Diagnostics
Christos Hatzis, PhD
Adjunct Associate Professor of Medicine, Section of Medical Oncology, Yale School of Medicine, Yale University, Clinical Mechanisms Lead, Translational Medicine, Bristol-Myers Squibb
Susan McClure
CEO & Founder, Genome Creative
Anthony Magliocco, MD
Chair of Anatomic Pathology at the Moffitt Cancer Center and Executive Director of Esoteric Laboratory Services & CEO and President Protean Biodiagnostics
Sony Tuteja, PharmD, MS
Research Assistant Professor in the Department of Medicine at the Perelman School of Medicine at the University of Pennsylvania.
George Lee, PhD
Digital Pathology Informatics Lead, Bristol Myers Squibb
Kelly E. Caudle, Pharm.D., Ph.D., BCPS
Clinical Pharmacogenetics Implementation Consortium (CPIC) Director at St. Jude Children’s Research Hospital & affiliate Assistant Professor at The University of Tennessee Health Science Center
Anil Parwani, MD, PhD
Vice Chair and Director, Anatomic Pathology, Department of Pathology, The Ohio State University Wexner Medical Center
Lori Anderson
Product Marketing Manager, XIFIN, Inc.
Shawn Glisson, MD
Medical Oncology/Hematology, Norton Cancer Institute
Okan Ekinci, MD, MBA
Chief Medical Officer, Roche Diagnostics Information Solutions
Julia A. Beaver, MD
Director, Division of Oncology Products 1 (DOP1), Office of Hematology and Oncology Products, FDA
Kenneth J. Pienta, M.D
The Donald S. Coffey Professor Urology, Director, Urology Research Laboratories, Professor Oncology, Pharmacology and Molecular Sciences, Chemical and Biomolecular Engineering
Peter Silvester
Senior Vice President and President, Life Sciences Solutions, Thermo Fisher Scientific
Luis Lasalvia, MD, MIB
Vice President, Global Medical Officer, Siemens Healthineers
Wendy Rubinstein, MD, PhD, FACP, FACMG
Deputy Medical Director of CancerLinQ®, a not-for-profit subsidiary of the American Society of Clinical Oncology (ASCO).
Robert H. Vonderheide, MD, DPhil
Director, Abramson Cancer Center, Perelman School of Medicine and the John H. Glick, MD Abramson Cancer Center’s Director Professor at the University of Pennsylvania
Erynn Gordon, MS, LCGC
VP of Clinical Operations, Genome Medical
Edward Abrahams, PhD
President, Personalized Medicine Coalition
Katie Johansen Taber, PhD
Director, Clinical Development, Myriad Women’s Health
John Quackenbush, PhD
Henry Pickering Walcott Professor of Computational Biology and Bioinformatics
Chair, Department of Biostatistics, Harvard University T.H. Chan School of Public Health
Jason H. Moore, PhD, FACMI
Edward Rose Professor of Informatics,Director, Institute for Biomedical Informatics,Director, Division of Informatics,
Department of Biostatistics, Epidemiology, & Informatics,Senior Associate Dean for Informatics ,The Perelman School of Medicine University of Pennsylvania
Erica Ramos, MS, LCGC
President, National Society of Genetic Counselors and Dir & Head of Clinical Business Development at Geisinger National Precision Health
David Roth, MD, PhD
Simon Flexner Professor and Chair of Pathology and Laboratory Medicine, Director, Penn Center for Precision Medicine, University of Pennsylvania Perelman School of Medicine
Amy M. Miller, PhD
President & CEO, Society for Women’s Health Research
Gary Palmer, MD
Chief Medical Officer, Tempus
Timothy A. Chan, MD, PhD
PaineWebber Chair in Cancer Genetics; Director, Immunogenomics and Precision Oncology Platform; Member, Human Oncology & Pathogenesis Program; Vice Chair, Department of Radiation Oncology; Director, Translational Oncology Division
Nicholas Dracopoli, PhD, Consultant
Arturo Loaiza-Bonilla, MD, MSEd, FACP
Vice Chair, CTCA Department of Medical Oncology, CTCA Philadelphia
Eric B Kmiec Ph.D
Director, Gene Editing Program,Senior Research Scientist, Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute
Stephanie Devaney, Ph.D
Deputy Director – All of Us Research Program, National Institutes of Health.
Tara Schmidlen, MS, CGC
Clinical Investigator / Genetic Counselor – Geisinger Health System
Andrey Antov, PhD, MBA
Program Director, Maine Cancer Genomics Initiative, The Jackson Laboratory
Ilan “Lanny” Kirsch, M.D.
Senior Vice President of Translational Medicine, Adaptive Biotechnologies
David B. Nash, MD, MBA
Dean Jefferson College of Population Health, Dr. Raymond C. & Doris N. Grandon Professor of Health Policy
Selin Kurnaz, Ph.D.
CEO – Massive Bio
Yves Lussier, MD, FACMI
Associate Vice President for Health Sciences and Chief Knowledge Officer, Executive Director, Center for Biomedical Informatics and Biostatistics, University of Arizona Health Sciences
Lorenz M. Mayr, Ph.D.
Chief Technology Officer (CTO), GE Healthcare Life Sciences
Lara Mangravite, Ph.D.
President, Sage Bionetworks
Benjamin Haibe-Kains , Ph.D.
Senior Scientist, Princess Margaret Cancer Centre (PM), University Health Network, and Associate Professor in the Medical Biophysics Department of the University of Toronto
Leslie Bucheit MS, CGC
Product Manager, Digital Products, Myriad Genetics
Michael Cantor, MD, MA
Executive Director, Clinical Informatics, Regeneron Genetics Center
Philip Empey, PharmD, PhD
Associate Director, Institute of Precision Medicine, University of Pittsburgh and UPMC.
Slava Akmaev is the Chief Technology Officer at Scipher Medicine. He is responsible for product development in precision medicine and early discovery efforts in drug development using the Network Medicine platform. He has been recognized as a leader in the adoption of the AI/ML technology in healthcare and drug development and is a frequent speaker at some of the most prolific industry events. Slava is the inventor on a number of issued and pending patent applications and has published more than 30 peer-reviewed articles in computational biology, artificial intelligence and molecular biology. Additionally, he authored book chapters and numerous scientific presentations and posters.
Lori Anderson is product marketing manager for precision medicine informatics at XIFIN, where she brings many years of experience in medical affairs and product portfolio management in the healthcare and life-sciences industries. Prior to joining XIFIN, Lori was the director of health economics and outcomes research at Quest Diagnostics where she defined the reimbursement strategy for numerous tests routinely used in precision medicine. As a laboratorian herself with a particular interest in hematological neoplasms and the role of platelets in cardiovascular disease, Lori has contributed to the publication of 10 book chapters, 20 peer reviewed publications and over 40 poster presentations and has presented on numerous topics in laboratory medicine and life sciences worldwide.
Kristine Ashcraft, BS, MBA is a molecular biologist by training and is CEO and founder of YouScript. She has worked in the precision medicine space since 2000 and was recently named one of the 25 leading voices in precision medicine. Kristine has authored multiple publications on the clinical and economic benefits of pharmacogenomic testing including one lauded as one of the most influential publications at an AMIA meeting. She has been interviewed by numerous media outlets including the New York Times, the Wall Street Journal, and NBC Nightly News and has spoken at SXSW, ASHG, and numerous precision medicine Conferences. She is committed to being a catalyst in the adoption of precision medicine.
Heather is a passionate professional that has worked within diagnostic medical imaging startups for over 15 years. Applying her software development and program management skills, she led a disciplined effort to earn a positive BCBS Evidence Street review, CMS New Technology APC payment classifications, Category III codes, and greater than 90% commercial coverage in 18 months for HeartFlow’s core technology, FFRct. Today, her leads her team to push the envelope on alternative payment models and value-based discussions with payers. Heather earned her Ph.D. in Biomedical Engineering from Vanderbilt University with a focus in neuroelectrophysiology.
An experienced healthcare executive with a proven track record of innovative value based reimbursement strategies, Lena Chaihorsky has spent her career studying reimbursement and the managed care industry from the perspective of diagnostics. With a background in biology and mathematics from Tufts, she has held leadership positions in sales, national contracting, and reimbursement for both start up and global diagnostics companies prior to co-Founding Alva10. Her thought leadership in payment innovation recently led to appointment on World Economic Forum working groups on Precision Medicine.
Dana is an accomplished and enthusiastic marketing professional with decades of experience in corporate marketing and publishing, membership, and partner/project management. After 25 years at National Geographic, she is now in a new career in the health and wellness arena at Inspire, the leading social network for health, who’s mission is to accelerate medical progress through a world of connected patients.
Tony Grover brings over 20 years of experience and expertise in business development, strategic partnerships, licensing, reimbursement and new technology platform development as an executive in the diagnostic and medical device industries. Tony has raised over $100M in cumulated capital, negotiated a variety of deals including licenses, strategic investment, joint ventures, and lab service agreements.
Patricia Goede is VP Clinical Informatics at XIFIN, Inc., where she brings 22 years’ experience developing biomedical imaging informatics solutions and technology to facilitate multi-modality and multispecialty image-based exchange, collaboration, and management in distributed environments. Goede founded VisualShare and served as CEO until its acquisition by XIFIN in 2015. Previously, Goede was at the University of Utah where she pioneered a number of image, visualization and collaboration tools. She is the founder of the Electronic Medical Education Resource Group (EMERG), and as its director, established the Utah Center of Excellence for Electronic Medical Education. Goede holds an MS in Computational Visualization and a PhD. in Biomedical Imaging Informatics.
Mark Hiatt, currently Vice President for a precision oncology company, has served as the Chief Medical Executive for a multi-state Blues plan and a National Medical Benefits Manager, and Department Leader and Board Member for a regional health system. Dr. Hiatt completed a fellowship in cardiovascular imaging at Stanford University, residency in radiology and master’s in Health Evaluation Sciences at the University of Virginia, and MD and MBA with academic distinction at Wake Forest University. He is the Chair of the Greater Salt Lake Chapter of the American Red Cross.
Dr. Hurban is Senior Director and Global Head of Translational Genomics at Q2 Solutions. In this role, he is responsible for the identification and implementation of new genomic capabilities, encompassing bioinformatics and wet-laboratory methods, as well as the development and validation of genomic assays to support research and clinical programs. These include broad-based screening assays, such as exome and RNA sequencing, to highly focused expression, genotyping and sequencing assay panels that target a smaller number of genes. Dr. Hurban has more than 25 years of experience in molecular genetics, including more than 18 years in positions of increasing responsibility in high-profile genomics-focused organizations. His research interests have focused on the genetic control of gene expression and have spanned diverse fields such as toxicology, developmental, and cancer biology.
Christiana Iyasere, MD, MBA, is a graduate of Yale College and Columbia University, College of Physicians and Surgeons. She completed her residency at Mass General in internal medicine in 2005. Following her tenure as a medical resident at Mass General, Dr. Iyasere undertook an administrative fellowship under the guidance of Dr. Peter Slavin, with an emphasis on technology evaluation, adoption and promotion. She subsequently went to Harvard Business School for continued management training and finished her degree in 2008. Since that 2008 Dr. Iyasere has been involved in the development of enterprise wide technology accelerators both for Partners Healthcare and Massachusetts General Hospital. She currently is the Director of the MGH Department of Medicine Innovation Program and is responsible for a portfolio of investments in therapeutics, informatics and digital health that have transformational potential in healthcare and is a co-founder of Dyrnamix, a cardiovascular diagnostics and informatic biotech.
Sheryl Krevsky Elkin, PhD, is the Chief Scientific Officer at N-of-One, a QIAGEN company. An early member of the N-of-One team, Dr. Elkin has led the interpretation of thousands of patient cases, establishing a rigorous process for the analysis of scientific and clinical evidence and presentation of molecular and clinical evidence to physicians to help guide their therapeutic decisions. Dr. Elkin has taken a lead role in the development of the N-of-One clinical interpretation methodology to support clinicians in identifying therapeutic strategies specific to each patient. Prior to joining N-of-One, Dr. Elkin completed her postdoctoral fellowship at the Massachusetts Institute of Technology’s Center for Cancer Research, where she earned a fellowship from the Leukemia and Lymphoma Society. She earned her doctorate in Biological and Biomedical Sciences from Harvard Medical School and an A.B. in Biology and Music from Amherst College, graduating Phi Beta Kappa and summa cum laude, with High Distinction in Biology.
Debbie Ledet is the Vice President of Market Access with Biotheranostics, Inc. Debbie has spent the past 20 years successfully securing medical policy coverage and reimbursement for diagnostics and medical devices in start-ups and Fortune 500 companies including Cytyc/Hologic, Natera, Liposcience, Gambro and Johnson & Johnson Medical, Inc. She has held multiple Executive Leadership roles building and directing successful Market Access teams responsible for coding, coverage, contracting and reimbursement within Commercial and Governmental health plans. Debbie is an active coalition member within The Coalition for 21st Century Medicine, the American Clinical Laboratory Association (ACLA) and the California Clinical Laboratory Association (CCLA) sitting on various billing, reimbursement and public policy workgroups within these organizations. Debbie holds a Bachelor’s degree from the University of Memphis and resides in Charlotte, NC.
Dr. Arturo Loaiza-Bonilla is the current Vice Chair of Medical Oncology of Research at Cancer Treatment Centers of America – ERMC, and also Co-Founder and Chief Medical Officer at Massive Bio (www.massivebio.com). A precision oncology expert with experience at the Abramson Cancer Center of the University of Pennsylvania, University of Miami, Johns Hopkins and the National Institutes of Health, his major interest focuses in the field of innovative approaches to match oncology patients to phase 1-3 clinical and translational research cancer trials, integrating next-generation personalized molecular diagnostics, immunotherapy, biomarkers, previous therapies, and the patient’s overall status under an Artificial Intelligence-based and machine learning platform, which integrates to the electronic medical record. His company and virtual tumor board / clinical trial matching platforms have been recently featured in GenomeWeb and MedPage Today, including a first-in-the-world registry, SYNERGY-AI to match cancer patients based on Artificial Intelligence (https://clinicaltrials.gov/ct2/show/NCT03452774)
Hannah Mamuszka is the Founder and CEO of Alva10, a company focused on driving up the value of diagnostics in healthcare. Ms Mamuszka founded Alva10 after having spent almost 20 years in the Cambridge, MA biotech community, with extensive experience in both drug and diagnostic development, validation, and commercialization. Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda).
Andrew Norden, MD, MPH, MBA, leads clinical strategy and execution at COTA. A renowned expert in real-world data and evidence and a sought after speaker and advisor on the topics, Dr.Norden is a trained neuro-oncologist, clinical researcher, and physician executive who joined COTA in 2017. Under his leadership, COTA built a scalable cancer-specific data model and approaches to clinical data curation and quality assurance that enable COTA’s provider and life sciences-facing applications. He is also responsible for COTA’s collaborative work with FDA, Friends of Cancer Research, and a number of additional partners.
David Parker, PhD, is Senior Vice President, Diagnostics Solutions at Precision for Medicine. He currently leads Precision for Medicine’s Diagnostics Solutions consulting practice and provides strategic advisory services to the firm’s diagnostics, device, and biopharma clients. David has well almost 35 years of experience in the healthcare industry, including 23 years of strategy consulting experience centered on the intersection of reimbursement, health economics, clinical science, and marketing strategy. His consulting encompasses all aspects of market access, reimbursement, evidence development strategy, and commercialization, with a particular focus on personalized medicine, advanced molecular and companion diagnostics, and targeted therapies.
John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard TH Chan School of Public Health and Professor of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute. John’s PhD was in Theoretical Physics, in 1992 he received a fellowship from the National Institutes of Health to work on the Human Genome Project, which led him from the Salk Institute to Stanford University to The Institute for Genomic Research (TIGR) before moving to Harvard in 2005. John’s research uses massive data from DNA sequencing and other assays to model functional networks in human cells. By comparing networks between groups of individuals, he has found new drug targets, explored chemotherapy resistance, and investigated differences between the sexes. He has made pioneering discoveries about how the genetic variants work together to determine our traits. John has published more than 280 papers; his work has been cited more than 65,000 times. He has received numerous awards for his work, including recognition in 2013 as a White House Open Science Champion of Change. He is also the co-founder of Genospace, a precision medicine software company that was purchased by the Hospital Corporation of America in 2017.
Sumanth currently functions as the EIR within the National Account division at Anthem and Chairman of his family office, Reddy Ventures. He is on the lookout for innovators that are like minded in the healthcare space that believe empathy and patient care should come 1st followed by profit and scale. He believes the future of healthcare delivery will be de-centralized through primary care, retail clinics and small footprint infrastructure where the foundational focus is on approachable and cost effective preventative and precision medicine platforms.
Dr. Schaecher has been active in managed care for over 20 years initially involved in utilization management, credentialing, formulary management and appeals for several managed care organizations in the late 1990’s. Employed by Intermountain Healthcare/SelectHealth from 1998 until 2017 and subsequently by University of Utah Health Plans his responsibilities have included quality improvement, medical policy development/implementation, new technology assessment, assisted with benefit design, fee schedule development, fraud/waste/abuse, medical coding and auditing, provider relations liaison and value-based programs. Throughout this time he has worked closely with pharmacy services at both plans in developing the plan formulary and has been active in the Pharmacy and Therapeutics committee at the Plan and system level working to align formularies so as to reduce administrative complexity and cost yet assuring appropriate patient access to important therapies.
Clynt Taylor is the Chief Executive Officer of Intervention Insights and a member of the company’s board of directors. He joined Insights in 2017 and brings over 20 years of experience in healthcare technology innovation, both as an entrepreneur and senior executive with startup and growing companies.
Matthew Tucker has been in healthcare for 20 years in commercial roles at startups and large multi-national companies such as Mylan, Baxter Healthcare, and Highmark Health. He has led brands and portfolios in medical devices and pharmaceuticals, as well as commercial programs such as Highmark’s Vital program. He also runs an independent consulting company helping medtech companies achieve commercial and customer success. He is the author of the book “The Selfish Career” and is on the Board of Directors of Facing Forward, a non-profit in Chicago working to end homelessness.
Debbie Windsor has 17 years in the health care landscape working with all channels within Health Care. She has worked with multiple levels of decision makers within including Hospitals, Physician Groups, Specialty Groups, IDN, Health Systems, Health Plans, and Lab Benefit Management. Debbie’s background helped her develop a deep understanding of clients and their needs and how to meet those needs with a consultative solution oriented approach. Working as Market Access Leader for five years has led her to a deep understanding of HEDIS/STAR ratings, Reimbursement and PAMA landscape, Technology, and Companion Diagnostics.
Kellie Yarnell is Vice President of Genomics Laboratories, where she leads the genomics efforts and organization. Previously, Kellie led genomic operations for Expression Analysis, an organization specializing in next-generation sequencing and bioinformatics services supporting the biopharmaceutical clinical trial and research market. Kellie brings more than 20 years of commercial expertise, scientific aptitude and strategic vision in the genomics space to the organization.